滤泡性淋巴瘤发病机制:从遗传学到微环境再到临床转化
滤泡性淋巴瘤(FL)在临床和生物学上均具有异质性。t(14;18) 易位不再被视为主要遗传驱动因素,表观遗传调节因子的反复遗传改变已成为该淋巴瘤亚型的核心标志。测序研究提供了额外遗传畸变的近乎完整目录,纵向和空间遗传学研究为早期进展者和转化等高风险表型提供了初步分子见解,并支持存在持续再增殖细胞作为淋巴瘤储库和FL复发预兆的证据。同时,对促进淋巴瘤发生和疾病进展的肿瘤微环境线索的理解不断拓宽,研究开始揭示遗传学、表观遗传学和微环境之间的汇聚与合作。亟需将生物学与治疗学结合,以优化患者选择并指导「正确药物用于正确患者」。
要点
- t(14;18) 易位不再是FL的主要遗传驱动因素,表观遗传调节因子反复突变成为核心标志。
- 纵向和空间遗传学研究为早期进展和转化等高风险表型提供初步分子见解。
- 持续再增殖细胞可能作为淋巴瘤储库和FL复发的预兆。
核心结论
- FL的发病机制涉及遗传学、表观遗传学和微环境的汇聚与合作,需将生物学与治疗学结合以优化患者选择和个体化治疗。
研究设计与样本
- 综述类文章,检索范围未在原文中报告。
主要发现
- t(14;18) 易位不再被视为主要遗传驱动因素,表观遗传调节因子的反复遗传改变已成为FL的核心标志。
- 测序研究提供了额外遗传畸变的近乎完整目录。
- 纵向和空间遗传学研究为早期进展者和转化等高风险表型提供初步分子见解,并支持存在持续再增殖细胞作为淋巴瘤储库和FL复发预兆。
- 对促进淋巴瘤发生和疾病进展的肿瘤微环境线索的理解不断拓宽,研究开始揭示遗传学、表观遗传学和微环境之间的汇聚与合作。
临床怎么用
- 将生物学见解与治疗学结合,以优化患者选择并指导「正确药物用于正确患者」。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Follicular lymphoma (FL) represents a heterogeneous disease both clinically and biologically. The pathognomonic t(14;18) translocation can no longer be thought of as the primary genetic driver, with increasing recognition of the biological relevance of recurrent genetic alterations in epigenetic regulators that now feature as a pivotal hallmark of this lymphoma subtype. Furthermore, sequencing studies have provided a near complete catalogue of additional genetic aberrations. Longitudinal and spatial genetic studies add an additional layer to the biological heterogeneity, providing preliminary molecular insights into high-risk phenotypes such as early progressors and transformation, and also supporting evidence for the existence of persisting re-populating cells that act as lymphoma reservoirs and harbingers for FL recurrence. Simultaneously, understanding of the tumour microenvironmental cues promoting lymphomagenesis and disease progression continue to broaden. More recently, studies are beginning to unravel the convergence and co-operation between the genetics, epigenetics and microenvironment. There is a pressing need to marry biology with therapeutics, especially with the burgeoning treatment landscape in FL, to aid in optimising patient selection and guiding the 'right drug to the right patient'.
引用
- Kumar E, Pickard L, Okosun J, et al. Pathogenesis of follicular lymphoma: genetics to the microenvironment to clinical translation. Br J Haematol. 2021. PMID: 33694181. doi:10.1111/bjh.17383
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。